Biomerica, Inc. (BMRA) financial statements (2022 and earlier)
Company profile
| Business Address |
17571 VON KARMAN AVENUE IRVINE, CA 92614 |
| State of Incorp. | DE |
| Fiscal Year End | May 31 |
| SIC | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 11/30/2021 Q2 | 8/31/2021 Q1 | 5/31/2021 Q4 | 2/28/2021 Q3 | 11/30/2020 Q2 | 8/31/2020 Q1 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 7,199 | 4,997 | 4,199 | 5,273 | 5,684 | 6,964 | ||
| Cash and cash equivalents | 7,199 | 4,997 | 4,199 | 5,273 | 5,684 | 6,964 | ||
| Receivables | 1,097 | 29 | 1,455 | 1,878 | 1,612 | 1,583 | ||
| Inventory, net of allowances, customer advances and progress billings | 2,982 | 2,862 | 3,206 | 2,860 | 4,198 | 4,101 | ||
| Inventory | 2,982 | 2,862 | 3,206 | 2,860 | 4,198 | 4,101 | ||
| Other undisclosed current assets | 1,125 | 1,058 | 370 | 774 | 453 | 471 | ||
| Total current assets: | 12,403 | 8,946 | 9,231 | 10,785 | 11,947 | 13,120 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 1,427 | 1,490 | 1,553 | 1,538 | 1,596 | 1,654 | ||
| Property, plant and equipment | 274 | 288 | 311 | 308 | 288 | 292 | ||
| Intangible assets, net (including goodwill) | 389 | 360 | 295 | 269 | 218 | 216 | ||
| Intangible assets, net (excluding goodwill) | 389 | 360 | 295 | 269 | 218 | 216 | ||
| Other noncurrent assets | 150 | 267 | 264 | 283 | 262 | 445 | ||
| Other undisclosed noncurrent assets | 165 | 165 | 165 | 165 | 165 | 165 | ||
| Total noncurrent assets: | 2,406 | 2,570 | 2,588 | 2,563 | 2,531 | 2,772 | ||
| TOTAL ASSETS: | 14,809 | 11,516 | 11,819 | 13,348 | 14,478 | 15,892 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 1,581 | 641 | 583 | 756 | 1,258 | 1,271 | ||
| Accounts payable | 432 | |||||||
| Accrued liabilities | 152 | |||||||
| Employee-related liabilities | 674 | 508 | 367 | 392 | 309 | |||
| Other undisclosed accounts payable and accrued liabilities | 906 | 134 | 389 | 866 | 962 | |||
| Other undisclosed current liabilities | 3,160 | 841 | 717 | 596 | 616 | 531 | ||
| Total current liabilities: | 4,741 | 1,482 | 1,300 | 1,352 | 1,874 | 1,801 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 1,167 | 1,231 | 1,292 | 1,396 | 1,455 | 1,510 | ||
| Operating lease, liability | 1,167 | 1,231 | 1,292 | 1,396 | 1,455 | 1,510 | ||
| Other undisclosed noncurrent liabilities | (1,167) | (1,231) | (1,292) | (1,396) | (1,455) | (1,510) | ||
| Total noncurrent liabilities: | 1,167 | 1,231 | 1,396 | 1,455 | 1,510 | |||
| Total liabilities: | 5,908 | 2,713 | 2,592 | 2,748 | 3,329 | 3,312 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 8,901 | 8,803 | 9,227 | 10,600 | 11,149 | 12,581 | ||
| Preferred stock | 26 | 26 | ||||||
| Common stock | 1,015 | 1,001 | 985 | 984 | 942 | 940 | ||
| Additional paid in capital | 41,159 | 39,945 | 38,837 | 36,564 | 35,285 | 35,231 | ||
| Accumulated other comprehensive loss | (58) | (54) | (48) | (49) | (43) | (42) | ||
| Accumulated deficit | (33,214) | (32,089) | (30,546) | (26,900) | (25,060) | (23,575) | ||
| Total stockholders' equity: | 8,901 | 8,803 | 9,227 | 10,600 | 11,149 | 12,581 | ||
| TOTAL LIABILITIES AND EQUITY: | 14,809 | 11,516 | 11,819 | 13,348 | 14,478 | 15,892 | ||
Income statement (P&L) ($ in thousands)
| 11/30/2021 Q2 | 8/31/2021 Q1 | 5/31/2021 Q4 | 2/28/2021 Q3 | 11/30/2020 Q2 | 8/31/2020 Q1 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 4,647 | 1,262 | 1,054 | 3,629 | 1,373 | 1,144 | |
| Cost of revenue | (3,875) | (1,351) | (1,194) | (3,667) | (1,011) | (961) | |
| Gross profit: | 772 | (89) | (140) | (39) | 361 | 183 | |
| Operating expenses | (1,902) | (1,451) | (2,344) | (1,842) | (1,841) | (1,839) | |
| Operating loss: | (1,130) | (1,540) | (2,483) | (1,880) | (1,480) | (1,656) | |
| Nonoperating income | 7 | 7 | 13 | 38 | 8 | 8 | |
| Investment income, nonoperating | 7 | 7 | 13 | 38 | 8 | 8 | |
| Interest and debt expense | (0) | (0) | |||||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (0) | 0 | |||||
| Loss from continuing operations before equity method investments, income taxes: | (1,123) | (1,534) | (2,471) | (1,842) | (1,472) | (1,648) | |
| Other undisclosed income from continuing operations before income taxes | 0 | ||||||
| Loss from continuing operations before income taxes: | (1,123) | (1,534) | (2,471) | (1,842) | (1,472) | (1,648) | |
| Income tax expense (benefit) | (2) | (9) | (2) | 3 | (13) | (1) | |
| Net loss available to common stockholders, diluted: | (1,125) | (1,543) | (2,472) | (1,839) | (1,485) | (1,649) | |
Comprehensive Income ($ in thousands)
| 11/30/2021 Q2 | 8/31/2021 Q1 | 5/31/2021 Q4 | 2/28/2021 Q3 | 11/30/2020 Q2 | 8/31/2020 Q1 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (1,125) | (1,543) | (2,472) | (1,839) | (1,485) | (1,649) | |
| Comprehensive loss: | (1,125) | (1,543) | (2,472) | (1,839) | (1,485) | (1,649) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (5) | (6) | 1 | (5) | (2) | (2) | |
| Comprehensive loss, net of tax, attributable to parent: | (1,130) | (1,548) | (2,472) | (1,845) | (1,487) | (1,651) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.